Key statistics
On Friday, Annovis Bio Inc (07X:DEU) closed at 7.77, 76.19% above the 52 week low of 4.41 set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.03 |
---|---|
High | 8.03 |
Low | 7.62 |
Bid | 7.53 |
Offer | 7.68 |
Previous close | 7.97 |
Average volume | 880.30 |
---|---|
Shares outstanding | 13.05m |
Free float | 10.24m |
P/E (TTM) | -- |
Market cap | 106.52m USD |
EPS (TTM) | -4.42 USD |
Data delayed at least 15 minutes, as of Nov 08 2024.
More ▼
Announcements
- Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
- Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
- FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
- Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
- Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
- Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
- Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
More ▼